Product
KH176
Aliases
Oral administration of 100 mg KH176 twice daily
1 clinical trial
6 indications
Indication
Mitochondrial DiseasesIndication
Mitochondrial EncephalomyopathyIndication
MELASIndication
CPEOClinical trial
A Phase IIb Open-label, Multi-centre, Extension Study to Explore the Long-term Safety and Efficacy of KH176 in Subjects With a Genetically Confirmed Mitochondrial DNA tRNALeu(UUR) m.3243A>G Mutation Who Have Completed the KHENERGYZE Study KH176-202.Status: Completed, Estimated PCD: 2023-06-01